Abstract
AbstractIn this study, we explored the feasibility of using real-world data (RWD) from a large clinical research network to simulate real-world clinical trials of Alzheimer’s disease (AD). The target trial (i.e., NCT00478205) is a Phase III double-blind, parallel-group trial that compared the 23 mg donepezil sustained release with the 10 mg donepezil immediate release formulation in patients with moderate to severe AD. We followed the target trial’s study protocol to identify the study population, treatment regimen assignments and outcome assessments, and to set up a number of different simulation scenarios and parameters. We considered two main scenarios: (1) a one-arm simulation: simulating a standard-of-care (SOC) arm that can serve as an external control arm; and (2) a two-arm simulation: simulating both intervention and control arms with proper patient matching algorithms for comparative effectiveness analysis. In the two-arm simulation scenario, we used propensity score matching controlling for baseline characteristics to simulate the randomization process. In the two-arm simulation, higher serious adverse event (SAE) rates were observed in the simulated trials than the rates reported in original trial, and a higher SAE rate was observed in the 23 mg arm than in the 10 mg SOC arm. In the one-arm simulation scenario, similar estimates of SAE rates were observed when proportional sampling was used to control demographic variables. In conclusion, trial simulation using RWD is feasible in this example of AD trial in terms of safety evaluation. Trial simulation using RWD could be a valuable tool for post-market comparative effectiveness studies and for informing future trials’ design. Nevertheless, such an approach may be limited, for example, by the availability of RWD that matches the target trials of interest, and further investigations are warranted.
Funder
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics,Computer Science Applications,Medicine (miscellaneous)
Reference34 articles.
1. Aronson, J. K. What is a clinical trial? Br. J. Clin. Pharmacol. 58, 1–3 (2004).
2. Sertkaya, A., Wong, H. H., Jessup, A. & Beleche, T. Key cost drivers of pharmaceutical clinical trials in the United States.Clin. Trials 13, 117–126 (2016).
3. Scott, T. J., O’Connor, A. C., Link, A. N. & Beaulieu, T. J. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Ann. NY Acad. Sci. 1313, 17–34 (2014).
4. Holford, N., Ma, S. C. & Ploeger, B. A. Clinical trial simulation: a review. Clin. Pharmacol. Ther. 88, 166–182 (2010).
5. Gal, J. et al. Optimizing drug development in oncology by clinical trial simulation: why and how? Brief. Bioinform. 19, 1203–1217 (2018).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献